Targets chemotherapy remains to play a leading role in the treatment for the majority of patients with advanced-stage LUAD, and EGFR-TKI is the first line drug for lung cancer patients harboring an EGFR mutation in routine clinical practice (Ciuleanu et al., 2012). Here, EGFR is linked to lung cancer.